Presentation is loading. Please wait.

Presentation is loading. Please wait.

Systemic reovirus treatment targets disseminated human myeloma in vivo

Published byΤρύφαινα Δουμπιώτης Modified over 5 years ago

Similar presentations

Presentation on theme: "Systemic reovirus treatment targets disseminated human myeloma in vivo"— Presentation transcript:

1 Systemic reovirus treatment targets disseminated human myeloma in vivo.
Systemic reovirus treatment targets disseminated human myeloma in vivo. RPMI 8226-GFP cells were injected into sublethally irradiated NOD/SCID mice and treated with a single intravenous injection of DV of LV (1 × 107 PFU). A, sacrificed mice were monitored for whole-body fluorescene of GFP+ multiple myeloma (MM) lesions. B, tumor collected from animals were analyzed for statistical differences, mean (n = 6) ± SE. C, bone marrow collected from mice was anlyzed for GFP+ MM cells by flow cytometry. Chandini M. Thirukkumaran et al. Clin Cancer Res 2012;18: ©2012 by American Association for Cancer Research

Download ppt "Systemic reovirus treatment targets disseminated human myeloma in vivo"

Similar presentations

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.
Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies in athymic nude mice bearing the s.c. Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies.

Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies in athymic nude mice bearing the s.c. Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies.
MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC.

MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC.
L-ICON1 is effective for the treatment of murine TNBC (4T1/Luc + GFP) in an orthotopic CDX model. L-ICON1 is effective for the treatment of murine TNBC.

L-ICON1 is effective for the treatment of murine TNBC (4T1/Luc + GFP) in an orthotopic CDX model. L-ICON1 is effective for the treatment of murine TNBC.
TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.

TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.
Effect of HA on hematopoietic recovery in tumor-bearing mice.

Effect of HA on hematopoietic recovery in tumor-bearing mice.
Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.
coTCRcys-transduced T cells control tumor growth in vivo.

coTCRcys-transduced T cells control tumor growth in vivo.
Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.
SBC-5 miR-335+ xenografts abrogated completely, or in part, skeletal osteolytic lesions in humanized NOD/SCID IL2Rγnull immunodeficient mice. SBC-5 miR-335+

SBC-5 miR-335+ xenografts abrogated completely, or in part, skeletal osteolytic lesions in humanized NOD/SCID IL2Rγnull immunodeficient mice. SBC-5 miR-335+
Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.

Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.
PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.
Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. A.

Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. A.
Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c
Matriptase-2 inhibited breast tumor development in vivo.

Matriptase-2 inhibited breast tumor development in vivo.
The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.
MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.

MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.
Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.
The antitumor and antimetastatic properties of PF-03084014 in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF-03084014 in the.

The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.
Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

Similar presentations

Ads by Google